Teva Pharmaceutical Industries (NYSE:TEVA) Shares Up 6.1%
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) shares shot up 6.1% during trading on Monday . The company traded as high as $7.44 and last traded at $7.44, 18,343,414 shares traded hands during trading. An increase of 16% from the average session volume of 15,806,336 shares. The stock had previously closed at $7.01.
TEVA has been the subject of a number of recent research reports. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Friday, July 5th. Wolfe Research began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 target price on the stock. Bank of America cut shares of Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $19.00 to $9.00 in a research note on Thursday, May 30th. Oppenheimer set a $12.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, June 12th. Finally, Cowen set a $9.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $12.80.
The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. The firm’s 50-day moving average is $7.21 and its 200 day moving average is $11.25. The stock has a market cap of $8.83 billion, a price-to-earnings ratio of 2.97, a price-to-earnings-growth ratio of 0.78 and a beta of 1.68.
Institutional investors and hedge funds have recently modified their holdings of the stock. First Interstate Bank purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $28,000. Pacer Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. Kavar Capital Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $35,000. G&S Capital LLC grew its holdings in shares of Teva Pharmaceutical Industries by 99.4% during the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after purchasing an additional 2,000 shares during the period. Finally, NEXT Financial Group Inc grew its holdings in shares of Teva Pharmaceutical Industries by 384.8% during the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares during the period. 57.85% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Candlestick
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.